BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17298625)

  • 1. Fast track referrals for colorectal cancer: the impact of the faecal occult blood test screening programme.
    Ward N; Wright J; Marsh S; Norton J
    Colorectal Dis; 2007 Mar; 9(3):258-61. PubMed ID: 17298625
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for colorectal cancer using faecal blood testing: varying the positive cut-off value.
    Edwards JB
    Pathology; 2005 Dec; 37(6):565-8. PubMed ID: 16373240
    [No Abstract]   [Full Text] [Related]  

  • 3. [Colorectal cancer screening: immunological test for faecal occult blood preferred].
    Jansen JB; van Rossum LG; Laheij RJ
    Ned Tijdschr Geneeskd; 2009; 153():A474. PubMed ID: 19785842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Faecal occult blood test and mass screening for colorectal cancer].
    Hiwatashi N; Shimada T
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():201-6. PubMed ID: 14574882
    [No Abstract]   [Full Text] [Related]  

  • 5. Experiences of patients with false positive results from colorectal cancer screening.
    Mant D; Fitzpatrick R; Hogg A; Fuller A; Farmer A; Verne J; Northover J
    Br J Gen Pract; 1990 Oct; 40(339):423-5. PubMed ID: 2271264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer (Br J Surg 2009; 96: 533-540).
    Nash GF
    Br J Surg; 2009 Aug; 96(8):956-7; author reply 957. PubMed ID: 19591144
    [No Abstract]   [Full Text] [Related]  

  • 7. [Arguments against implementing a population-based screening programme for colorectal cancer].
    Bonneux L
    Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1777. PubMed ID: 18754310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer screening using immunochemical faecal occult blood testing in Japan.
    Saito H
    J Med Screen; 2006; 13 Suppl 1():S6-7. PubMed ID: 17227634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Colorectal cancer screening is profitable].
    Pikkarainen P
    Duodecim; 1999; 115(17):1813-4. PubMed ID: 11941648
    [No Abstract]   [Full Text] [Related]  

  • 10. A 25-year follow-up of a population screened with faecal occult blood test in Finland.
    Malila N; Hakama M; Pukkala E
    Acta Oncol; 2007; 46(8):1103-6. PubMed ID: 17851857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.
    Lindholm E; Brevinge H; Haglind E
    Br J Surg; 2008 Aug; 95(8):1029-36. PubMed ID: 18563785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Feasibility of colorectal cancer screening with fecal occult blood test distributed by public pharmacies].
    Pippa G; Ferrara M; Valle S; Diego B; Alessandra B; Apuzzo M; Bazuro ME; Tammaro G; Federici A
    Recenti Prog Med; 2009; 100(7-8):348-51. PubMed ID: 19725474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence.
    Grazzini G; Ciatto S; Cislaghi C; Castiglione G; Falcone M; Mantellini P; Zappa M;
    J Med Screen; 2008; 15(4):175-81. PubMed ID: 19106257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Green-coloured results on guaiac-based faecal occult blood testing should be considered positive.
    Skitek M
    Ann Clin Biochem; 2005 May; 42(Pt 3):234-5; author reply 235. PubMed ID: 15949162
    [No Abstract]   [Full Text] [Related]  

  • 15. Is dietary restriction always necessary in Haemoccult screening for colorectal neoplasia?
    Robinson MH; Thomas WM; Pye G; Hardcastle JD; Mangham CM
    Eur J Surg Oncol; 1993 Dec; 19(6):539-42. PubMed ID: 8270040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
    Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
    Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
    J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric cancer after positive screening faecal occult blood testing and negative assessment.
    Zappa M; Visioli CB; Ciatto S; Grazzini G; Rubeca T; Bonanomi AG; Confortini M; Paci E; Castiglione G
    Dig Liver Dis; 2007 Apr; 39(4):321-6. PubMed ID: 17314076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for colorectal cancer with Hemoccult-II in the average risk population.
    Kronborg O
    Gastroenterol Clin Biol; 1998 Mar; 22(3 Suppl):S44-8. PubMed ID: 9762237
    [No Abstract]   [Full Text] [Related]  

  • 20. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
    Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.